Puma Biotechnology, Inc. (PBYI) Reaches $99.25 After 9.00% Up Move; Mylan N.V. (MYL) Had 13 Bulls

January 14, 2018 - By Michael Collier

The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) is a huge mover today! The stock increased 3.71% or $3.55 during the last trading session, reaching $99.25. About 1.07M shares traded or 44.50% up from the average. Puma Biotechnology, Inc. (NASDAQ:PBYI) has risen 23.65% since January 14, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.The move comes after 9 months positive chart setup for the $3.73 billion company. It was reported on Jan, 14 by Barchart.com. We have $108.18 PT which if reached, will make NASDAQ:PBYI worth $335.25M more.

Among 21 analysts covering Mylan Inc. (NASDAQ:MYL), 13 have Buy rating, 0 Sell and 8 Hold. Therefore 62% are positive. Mylan Inc. had 60 analyst reports since July 27, 2015 according to SRatingsIntel. On Monday, October 23 the stock rating was maintained by Mizuho with “Buy”. As per Monday, May 22, the company rating was upgraded by Barclays Capital. The rating was maintained by RBC Capital Markets on Tuesday, September 6 with “Sector Perform”. As per Thursday, December 21, the company rating was maintained by Cantor Fitzgerald. Citigroup downgraded the shares of MYL in report on Thursday, January 5 to “Neutral” rating. The rating was downgraded by Cowen & Co on Monday, July 27 to “Market Perform”. Cowen & Co maintained Mylan N.V. (NASDAQ:MYL) on Wednesday, October 4 with “Hold” rating. As per Monday, December 4, the company rating was maintained by UBS. The stock of Mylan N.V. (NASDAQ:MYL) earned “Hold” rating by Zacks on Thursday, August 27. The stock of Mylan N.V. (NASDAQ:MYL) has “Buy” rating given on Tuesday, November 7 by Susquehanna. See Mylan N.V. (NASDAQ:MYL) latest ratings:

11/01/2018 Broker: Goldman Sachs Rating: Buy New Target: $52.0 Upgrade
04/01/2018 Broker: Citigroup Rating: Buy New Target: $58.0 Maintain
03/01/2018 Broker: Leerink Swann Rating: Market Perform New Target: $44 Initiates Coverage On
21/12/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $41.0 Maintain
12/12/2017 Broker: Guggenheim Rating: Buy New Target: $59.0 Initiate
04/12/2017 Broker: UBS Rating: Buy New Target: $46.0 Maintain
07/11/2017 Broker: Susquehanna Rating: Buy New Target: $47.0 Maintain
30/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $45.0 Maintain
23/10/2017 Broker: Mizuho Rating: Buy New Target: $37.0 Maintain
20/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $32.0 Maintain

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. The company has market cap of $3.73 billion. The Company’s drug candidates include PB272 ) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). It currently has negative earnings. The firm also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Investors sentiment increased to 1.55 in Q3 2017. Its up 0.34, from 1.21 in 2017Q2. It is positive, as 19 investors sold Puma Biotechnology, Inc. shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. Qs Invsts Ltd Liability Corporation accumulated 1,000 shares. Emory University reported 1.95% stake. Covington Capital Mngmt holds 0% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 250 shares. Schwab Charles Management holds 0.01% or 135,167 shares in its portfolio. Moreover, Jane Street Group Inc Ltd Liability has 0.01% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 15,290 shares. Meeder Asset Mgmt holds 0% or 88 shares. California State Teachers Retirement Sys holds 0.01% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 45,990 shares. Fincl Bank Of Montreal Can owns 94,246 shares for 0.01% of their portfolio. Glenmede Tru Company Na invested 0% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). 3,009 were accumulated by Great West Life Assurance Com Can. Huntington Bank owns 100 shares. Northwestern Mutual Wealth accumulated 50 shares. Fisher Asset Ltd Liability Corp holds 0% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 15,545 shares. Ghost Tree Limited, a New York-based fund reported 65,000 shares. Endurant Mgmt Limited Partnership, a California-based fund reported 21,400 shares.

Since September 6, 2017, it had 0 insider purchases, and 2 insider sales for $3.30 million activity. BRYCE RICHARD PAUL sold $1.80M worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) on Friday, September 29.

Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on March, 7. They expect $-2.04 EPS, 0.00% or $0.00 from last year’s $-2.04 per share. After $-2.07 actual EPS reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts -1.45% EPS growth.

The stock increased 0.41% or $0.19 during the last trading session, reaching $46.9. About 5.82 million shares traded. Mylan N.V. (NASDAQ:MYL) has declined 7.73% since January 14, 2017 and is downtrending. It has underperformed by 24.43% the S&P500.

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company has market cap of $25.16 billion. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 29 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>